The purpose of this study is to describe the real-life use of Cabometyx® in monotherapy or in combination with nivolumab in Belgium in patients with advanced or metastatic Renal Cell Carcinoma (1st, 2nd and later lines of treatment)
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Treatment line
Timeframe: Baseline
Dose reductions and reasons
Timeframe: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Treatment interruptions and reason
Timeframe: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Treatment discontinuations and reason
Timeframe: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Alternative dose schedule
Timeframe: From baseline until the end of study up to 9 months
Mean number of any dose modification
Timeframe: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Median number of any dose modification
Timeframe: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Median time to any first dose modification
Timeframe: From baseline up to 6 to 8 weeks after cabozantinib initiation and within 10 days of cabozantinib stop
Median time to end of treatment
Timeframe: From baseline until the end of study up to 9 months
Duration of treatment exposure
Timeframe: From baseline until the end of study up to 9 months
Dose prescribed at initiation
Timeframe: Baseline
Average daily dose
Timeframe: From baseline until the end of study up to 9 months